Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Fluoxetine for Multiple Sclerosis Publisher



Hosseini R1 ; Tajdini M2 ; Modabbernia A3 ; Akhondzadeh S4 ; Tafakhori A5
Authors

Source: Cochrane Database of Systematic Reviews Published:2018


Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The objectives of this review is to assess the efficacy and safety of fluoxetine to modify the course of the disease in people with multiple sclerosis. © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Related Docs
View other Related Docs
1. Consensus Recommendations for the Diagnosis and Treatment of Multiple Sclerosis: The Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (Menactrims), Current Medical Research and Opinion (2015)
2. Consensus Recommendations for the Diagnosis and Treatment of Multiple Sclerosis: 2019 Revisions to the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2020)
3. The Effects of Omega-3 Supplementation on the Expanded Disability Status Scale and Inflammatory Cytokines in Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis, CNS and Neurological Disorders - Drug Targets (2019)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (9)
Roya Abolfazli (2)
Other Related Docs
4. Stem Cell Therapy for Multiple Sclerosis, Cochrane Database of Systematic Reviews (2018)
5. Increased Serum Brain-Derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-B and Its Impact on Functional Abilities, Neurologist (2015)
6. Efficacy and Safety of Peginterferon Beta-1A Compared to Interferon Beta-1A in Relapsing Remitting Multiple Sclerosis Patients: A Phase 3, Randomized, Non-Inferiority Clinical Trial (Pegintegrity), Multiple Sclerosis and Related Disorders (2024)
7. Osteopontin (Opn) As a Csf and Blood Biomarker for Multiple Sclerosis: A Systematic Review and Meta-Analysis, PLoS ONE (2018)
8. Disease-Modifying Therapies and T1 Hypointense Lesions in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis, CNS Neuroscience and Therapeutics (2022)
9. Consensus Recommendations for Diagnosis and Treatment of Multiple Sclerosis: 2023 Revision of the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2024)
10. Smoking and Worsening Disability in Multiple Sclerosis: A Meta-Analysis, Acta Neurologica Scandinavica (2018)
11. Low Dose Aspirin for Ms-Related Fatigue: Results of a Pilot, Double-Blind, Randomized Trial, Neurology Psychiatry and Brain Research (2017)
12. Multiple Sclerosis Epidemiology in East Asia, South East Asia and South Asia: A Systematic Review, Neuroepidemiology (2016)
13. Alternate Dosing of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Current Journal of Neurology (2023)
14. Clinical Characteristics and Disability Progression of Early-And Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis, Journal of Clinical Medicine (2020)
15. Adverse Drug Reactions of Multiple Sclerosis Diseasemodifying Drugs, Basic and Clinical Neuroscience (2023)
16. Multiple Sclerosis: Clinical Features, Pathophysiology, Diagnosis, and Management, Neuroinflammation (2018)
17. Post Marketing New Adverse Effects of Oral Therapies in Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2022)
18. Genetic Polymorphisms and Epigenetic Regulation of Survivin Encoding Gene, Birc5, in Multiple Sclerosis Patients, BMC Immunology (2019)
19. Identification of the Most Cost-Saving Disease-Modifying Therapies and Factors Affecting the Budget in the Pharmacotherapy of Multiple Sclerosis: A Systematic Review, European Journal of Clinical Pharmacology (2025)
20. An Interleukin 12 B Single Nucleotide Polymorphism Increases Il-12P40 Production and Is Associated With Increased Disease Susceptibility in Patients With Relapsing-Remitting Multiple Sclerosis, Neurological Research (2017)